製薬市場- 成長、将来展望、競合分析、2024年～2032年

製薬市場とは、急成長が期待され、世界の医薬品業界においてますます重要な役割を担う新興国の医薬品市場を指します。これらの市場の特徴は、人口の多さ、中間層の増加、ヘルスケアインフラの改善、医療へのアクセスの増加であり、これらが医薬品需要を牽引しています。製薬市場は、2032年までに11.5%の成長が見込まれています。製薬市場を簡単に概観すると、その成長に影響を与えるいくつかの主な要因が浮かび上がってくる。第一に、新興諸国の経済発展は可処分所得の増加と健康意識の向上につながり、ヘルスケアサービスや製品に対する需要の増加に寄与しています。第二に、これらの地域の政府は病院や診療所を含むヘルスケアインフラに多額の投資を行っており、幅広い治療へのアクセシビリティを高めています。さらに、医薬品の現地生産を奨励することを目的とした規制改革や政府の支援政策が、国内企業の成長を刺激し、外資を誘致しています。最後に、人口の急増と相まって慢性疾患の有病率が高まっていることから、ヘルスケアサービスと医薬品を拡大する必要性が高まっています。

経済成長とヘルスケア支出の増加

製薬市場の主な促進要因のひとつは、新興国で見られる力強い経済成長であり、これがヘルスケア支出の増加につながっています。中国、インド、ブラジルのような国々ではGDPが成長し、それに伴って可処分所得と生活水準が上昇しています。この経済的繁栄により、より多くの人々がヘルスケアサービスや医薬品を購入できるようになった。これらの国の政府政策は、国民皆保険の実現とヘルスケアインフラの改善を目指してヘルスケア予算の配分を増やすことで、この動向をさらに後押ししています。このようなヘルスケアへの投資の急増は、治療の有効性を高めるだけでなく、国民の健康意識全般を高め、医薬品需要の増加につながります。

ヘルスケアインフラの拡大

製薬市場における大きなビジネスチャンスは、ヘルスケアインフラの拡大にあります。新興国では、人口増加に伴いヘルスケアへのアクセスを向上させるため、病院、クリニック、流通網の整備が急速に進んでいます。この拡大は都市部にとどまらず、歴史的に医療サービスが行き届いていなかった農村部にも及んでいます。ヘルスケア施設の増加には、それに対応する医薬品の供給量の増加が必要であり、製薬企業にとって新市場への参入と強固な流通チャネル確立の大きなチャンスとなっています。

規制の不均一性

規制の不均一性が製薬市場の主要な抑制要因となっています。新興市場には、国によって大きく異なる多様で発展的な規制の枠組みが存在することが多いです。この多様性は、複数の市場で同時に製品を上市しようとする製薬企業にとって課題となりうる。このような異なる規制環境に対応するためには、多大なリソースと専門知識が必要となるため、製品の上市が遅れたり、市場参入のコストが増大したりする可能性があります。

現地メーカーとの競合

製薬市場における大きな課題は、現地製薬メーカーとの競合です。こうした現地メーカーは、地域の市場力学や規制のニュアンスをよく理解していることが多いです。また、現地のヘルスケアシステム内に確立された関係があり、現地の消費者から好意的に見られている可能性もあります。さらに、現地のメーカーは労働力や原材料が安いため、より低コストで医薬品を製造できることが多く、国際的な企業が価格で競争することを難しくしています。このような熾烈な競争により、多国籍製薬企業は、これらの地域で足場を固め、プレゼンスを拡大するために、製品の提供、市場戦略、価格設定モデルなどの面でイノベーションを起こす必要があります。

製品別：市場セグメンテーション

製薬市場を製品別に分類すると、医薬品とヘルスケアの2つが重要なカテゴリーであることがわかる。医薬品は、新興市場における疾病負担の増大と医療アクセスの拡大により、医薬品に対するニーズが持続しているため、一貫して最も高い収益を牽引しています。このセグメントは、継続的な薬剤介入を必要とする慢性疾患の蔓延と、伝染病に必要な急性治療の両方から利益を得ています。一方、サービス、ヘルスケアIT、医療機器を含むヘルスケア分野は、年間平均成長率（CAGR）が最も高くなると予測されています。この急成長の背景には、医療インフラを改善するための政府の取り組み、病院施設に対する民間投資の増加、より効率的な医療提供システムを求める世界の動きに対応した遠隔医療やデジタルヘルスソリューションの重視の高まりがあります。

適応症別：市場セグメンテーション

適応症別の市場セグメンテーションには、生活習慣病、がん・自己免疫疾患、感染症、その他が含まれます。がん・自己免疫疾患分野は、治療費の高騰と、これらの複雑な病態を対象とした医薬品イノベーションの進行が主な要因となって、最も高い収益が見込まれます。加えて、人口の高齢化と欧米型ライフスタイルの普及に伴い、新興市場でこれらの疾患の有病率が高まっていることも、この動向に拍車をかけています。逆に、糖尿病や高血圧などの生活習慣病を扱う分野は、CAGRが最も高くなると予想されています。この成長の主な要因は、食生活の変化、都市化の進展、座りがちなライフスタイルの増加によって、新興市場の人口の間でこれらの疾患が急速に増加していることです。

流通チャネル別：市場セグメンテーション

流通チャネル別の市場細分化については、病院と小売薬局が主要企業です。病院は、入院および外来患者ケアの両方を提供する主要な医療サービス提供拠点であるため、このセグメントで最も高い収益を占めています。総合的な治療が必要とされ、専門的な医薬品が必要とされることから、病院が圧倒的な収益を上げています。小売薬局のCAGRが最も高いと予測されるのは、セルフメディケーションの傾向の高まり、アクセスの利便性の向上、都市部や農村部での薬局ネットワークの拡大によるものです。さらに、チェーン薬局を通じた医薬品小売への信頼の高まりと、ジェネリック医薬品の受け入れ拡大が、この成長に重要な役割を果たしています。さらに、eコマースチャネルは、オンライン注文の利便性とインターネットサービスの普及拡大により急速に支持を集めており、新興市場の医薬品流通状況における消費者行動の潜在的な変化を示しています。

地域別の洞察

製薬市場において、地理的動向は各地域の著しい成長を浮き彫りにしており、中でもアジア太平洋地域は年間平均成長率（CAGR）および売上高ともにトップです。2023年には、中国やインドのような国々が、人口の多さ、医療費の増加、医薬品製造能力の拡大により、市場収益を独占しました。これらの国々は、政府の支援政策と中産階級の台頭により、医薬品の技術革新と生産の拠点となっています。2024年から2032年までの予測期間を見ても、アジア太平洋地域は、都市化の進展、ヘルスケアインフラの整備、慢性疾患の増加により、成長率でリードを維持すると予想されます。ラテンアメリカと東欧も、医療改革と経済開拓という同様の動向に牽引され、顕著な成長を遂げることが予想されるが、市場全体のシェアはアジア太平洋に比べるとまだ小さいです。

競合動向

競合動向という点では、市場競争は大手製薬企業間の激しい競争と地域新規参入企業のダイナミックな参入が混在しているのが特徴です。2023年には、Abbott Laboratories、Koninklijke Philips N.V.、F. Hoffmann-La Roche Ltd.、Merck &Co., Inc.、Novartis AG、Johnson &Johnson、Teva Pharmaceutical Industries Ltd.、AstraZeneca、GlaxoSmithKline plc、Lupin、Tata Consultancy Services Ltd.、Sun Pharmaceutical Industries Ltd.、Huadong Medicine Co., Ltd.などの主要企業が、広範な製品ポートフォリオと強固な販売網を活用することで、大きな収益を上げています。これらの企業は、戦略的提携、合併、買収に重点を置いて市場での地位を固める一方、複雑な疾患に対する新たな治療法を革新するために研究開発に多額の投資を行っています。2024年から2032年までの予測期間を見ても、これらの企業は引き続き未開拓市場への進出に重点を置き、特にジェネリック医薬品や生物製剤に大きな成長機会を提供すると予想されます。さらに、インドや中国のような地域では、現地メーカーがコスト面での優位性や現地の規制支援を活用することで市場での存在感を強め、競合情勢を激化させると予想されます。これらの動向は、製薬市場の戦略的方向性を決定づけるものであり、企業はこれらのダイナミックな地域における進化するヘルスケア需要や規制環境に絶えず適応していくことになります。

本レポートでお答えする主な質問

製薬市場の成長に影響を与える主なミクロおよびマクロ環境要因は何か？

現在および予測期間中の製品セグメントおよび地域に関する主要な投資ポケットは何か？

2032年までの推定推計・市場予測

予測期間中にCAGRが最も速いセグメントは？

市場シェアの大きいセグメントとその理由は？

中低所得国は製薬市場に投資しているか？

製薬市場で最大の地域市場はどこか？

アジア太平洋、ラテンアメリカ、中東・アフリカなどの新興市場における市場動向と力学は？

製薬市場の成長を促進する主要動向は？

世界の製薬市場で存在感を高めるための主要な競合企業とその主要戦略とは？

目次

第1章 序文

• レポート内容
  • レポートの目的
  • 対象者
  • 主な提供
• 市場セグメンテーション
• 調査手法
  • フェーズⅠ-二次調査
  • フェーズⅡ-一次調査
  • フェーズⅢ-有識者レビュー
  • 前提条件
  • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 製薬市場：競合分析

• 主要ベンダーの市場ポジショニング
• ベンダーが採用した戦略
• 主要な産業戦略
• ティア分析：2023 vs 2032

第4章 製薬市場：マクロ分析と市場力学

• イントロダクション
• 世界の製薬市場金額 2022-2032
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析
• ポーターのファイブフォースモデル
  • サプライヤーパワー
  • バイヤーパワー
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • テクノロジーの情勢
  • 法的な情勢
  • 社会情勢

第5章 製薬市場：製品別 2022-2032

• 市場概要
• 成長・収益分析：2023 vs 2032
• 市場セグメンテーション
  • 医薬品
    • ブランド処方薬
    • ジェネリック医薬品
    • 市販薬
  • ヘルスケア
    • 医療機器
    • 診断機器
    • その他（ITおよび記録管理）

第6章 製薬市場：適応症別 2022-2032

• 市場概要
• 成長・収益分析：2023 vs 2032
• 市場セグメンテーション
  • 生活習慣病
  • がんと自己免疫疾患
  • 感染症
  • その他

第7章 製薬市場：流通チャネル別 2022-2032

• 市場概要
• 成長・収益分析：2023 vs 2032
• 市場セグメンテーション
  • 病院
  • クリニック
  • 小売薬局
  • eコマース
  • ドラッグストア

第8章 北米の製薬市場 2022-2032

• 市場概要
• 製薬市場：製品別 2022-2032
• 製薬市場：適応症別 2022-2032
• 製薬市場：流通チャネル別 2022-2032
• 製薬市場：地域別 2022-2032
  • 北米
    • 米国
    • カナダ
    • その他北米地域

第9章 英国と欧州連合の製薬市場 2022-2032

• 市場概要
• 製薬市場：製品別 2022-2032
• 製薬市場：適応症別 2022-2032
• 製薬市場：流通チャネル別 2022-2032
• 製薬市場：地域別 2022-2032
  • 英国と欧州連合
    • 英国
    • ドイツ
    • スペイン
    • イタリア
    • フランス
    • その他欧州地域

第10章 アジア太平洋の製薬市場 2022-2032

• 市場概要
• 製薬市場：製品別 2022-2032
• 製薬市場：適応症別 2022-2032
• 製薬市場：流通チャネル別 2022-2032
• 製薬市場：地域別 2022-2032
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域

第11章 ラテンアメリカの製薬市場 2022-2032

• 市場概要
• 製薬市場：製品別 2022-2032
• 製薬市場：適応症別 2022-2032
• 製薬市場：流通チャネル別 2022-2032
• 製薬市場：地域別 2022-2032
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域

第12章 中東・アフリカの製薬市場 2022-2032

• 市場概要
• 製薬市場：製品別 2022-2032
• 製薬市場：適応症別 2022-2032
• 製薬市場：流通チャネル別 2022-2032
• 製薬市場：地域別 2022-2032
  • 中東・アフリカ
    • GCC
    • アフリカ
    • その他中東・アフリカ地域

第13章 企業プロファイル

• Abbott Laboratories
• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Novartis AG
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca
• GlaxoSmithKline plc
• Lupin
• Tata Consultancy Services Ltd.
• Sun Pharmaceutical Industries Ltd.
• Huadong Medicine Co. Ltd.
• その他の主要企業

List of Tables

• TABLE 1 Global Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 2 Global Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 3 Global Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 4 Global Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 5 Global Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 6 Global Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 7 North America Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 8 North America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 9 North America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 10 North America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 11 North America Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 12 North America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 13 U.S. Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 14 U.S. Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 15 U.S. Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 16 U.S. Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 17 U.S. Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 18 U.S. Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 19 Canada Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 20 Canada Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 21 Canada Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 22 Canada Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 23 Canada Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 24 Canada Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 25 Rest of North America Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 26 Rest of North America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 27 Rest of North America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 28 Rest of North America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 29 Rest of North America Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 30 Rest of North America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 31 UK and European Union Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 32 UK and European Union Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 33 UK and European Union Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 34 UK and European Union Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 35 UK and European Union Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 36 UK and European Union Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 37 UK Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 38 UK Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 39 UK Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 40 UK Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 41 UK Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 42 UK Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 43 Germany Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 44 Germany Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 45 Germany Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 46 Germany Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 47 Germany Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 48 Germany Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 49 Spain Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 50 Spain Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 51 Spain Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 52 Spain Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 53 Spain Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 54 Spain Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 55 Italy Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 56 Italy Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 57 Italy Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 58 Italy Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 59 Italy Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 60 Italy Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 61 France Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 62 France Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 63 France Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 64 France Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 65 France Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 66 France Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 67 Rest of Europe Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 68 Rest of Europe Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 69 Rest of Europe Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 70 Rest of Europe Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 71 Rest of Europe Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 72 Rest of Europe Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 73 Asia Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 74 Asia Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 75 Asia Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 76 Asia Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 77 Asia Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 78 Asia Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 79 China Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 80 China Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 81 China Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 82 China Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 83 China Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 84 China Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 85 Japan Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 86 Japan Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 87 Japan Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 88 Japan Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 89 Japan Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 90 Japan Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 91 India Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 92 India Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 93 India Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 94 India Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 95 India Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 96 India Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 97 Australia Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 98 Australia Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 99 Australia Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 100 Australia Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 101 Australia Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 102 Australia Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 103 South Korea Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 104 South Korea Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 105 South Korea Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 106 South Korea Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 107 South Korea Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 108 South Korea Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 109 Latin America Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 110 Latin America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 111 Latin America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 112 Latin America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 113 Latin America Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 114 Latin America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 115 Brazil Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 116 Brazil Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 117 Brazil Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 118 Brazil Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 119 Brazil Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 120 Brazil Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 121 Mexico Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 122 Mexico Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 123 Mexico Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 124 Mexico Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 125 Mexico Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 126 Mexico Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 127 Rest of Latin America Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 128 Rest of Latin America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 129 Rest of Latin America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 130 Rest of Latin America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 131 Rest of Latin America Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 132 Rest of Latin America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 133 Middle East and Africa Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 134 Middle East and Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 135 Middle East and Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 136 Middle East and Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 137 Middle East and Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 138 Middle East and Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 139 GCC Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 140 GCC Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 141 GCC Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 142 GCC Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 143 GCC Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 144 GCC Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 145 Africa Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 146 Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 147 Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 148 Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 149 Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 150 Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
• TABLE 151 Rest of Middle East and Africa Pharmerging Market By Product, 2022-2032, USD (Million)
• TABLE 152 Rest of Middle East and Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 153 Rest of Middle East and Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 154 Rest of Middle East and Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 155 Rest of Middle East and Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

• TABLE 156 Rest of Middle East and Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)

List of Figures

• FIG. 1 Global Pharmerging Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Pharmerging Market: Quality Assurance
• FIG. 5 Global Pharmerging Market, By Product, 2023
• FIG. 6 Global Pharmerging Market, By Indication, 2023
• FIG. 7 Global Pharmerging Market, By Distribution Channel, 2023
• FIG. 8 Global Pharmerging Market, By Geography, 2023
• FIG. 9 Market Geographical Opportunity Matrix - Global Pharmerging Market, 2023

FIG. 10Market Positioning of Key Pharmerging Market Players, 2023

FIG. 11Global Pharmerging Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

• FIG. 12 Global Pharmerging Market, By Product, 2023 Vs 2032, %
• FIG. 13 Global Pharmerging Market, By Indication, 2023 Vs 2032, %
• FIG. 14 Global Pharmerging Market, By Distribution Channel, 2023 Vs 2032, %
• FIG. 15 U.S. Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 16 Canada Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 17 Rest of North America Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 18 UK Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 19 Germany Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 20 Spain Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 21 Italy Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 22 France Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 23 Rest of Europe Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 24 China Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 25 Japan Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 26 India Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 27 Australia Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 28 South Korea Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 29 Rest of Asia Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 30 Brazil Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 31 Mexico Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 32 Rest of Latin America Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 33 GCC Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 34 Africa Pharmerging Market (US$ Million), 2022 - 2032
• FIG. 35 Rest of Middle East and Africa Pharmerging Market (US$ Million), 2022 - 2032

The pharmerging market refers to pharmaceutical markets in emerging economies that are expected to grow rapidly and play an increasingly significant role in the global pharmaceutical industry. These markets are characterized by their large populations, rising middle class, improving healthcare infrastructure, and increasing access to medical care, which collectively drive the demand for pharmaceutical products. The pharmerging market is expected to grow at 11.5% by 2032. A brief overview of the pharmerging market highlights several key factors influencing its growth. First, economic development in these countries leads to higher disposable incomes and greater health awareness, contributing to a higher demand for healthcare services and products. Second, governments in these regions are making significant investments in healthcare infrastructure, including hospitals and clinics, which increases accessibility to a wider range of medical treatments. Additionally, regulatory reforms and supportive government policies aimed at encouraging local production of pharmaceuticals stimulate the growth of domestic companies and attract foreign investment. Finally, the increasing prevalence of chronic diseases, coupled with a burgeoning population, underscores the need for expanded healthcare services and pharmaceutical products.

Economic Growth and Increased Healthcare Spending

One of the primary drivers of the pharmerging market is the robust economic growth observed in emerging economies, which has led to increased healthcare spending. As countries like China, India, and Brazil experience GDP growth, there is a corresponding rise in disposable incomes and living standards. This economic prosperity allows more people to afford healthcare services and pharmaceuticals. Government policies in these countries further support this trend by increasing healthcare budget allocations, aiming to provide universal health coverage and improve healthcare infrastructure. This surge in healthcare investment not only boosts the availability of medical treatments but also enhances the overall health awareness among the populace, leading to increased demand for pharmaceutical products.

Expansion of Healthcare Infrastructure

A significant opportunity within the pharmerging market lies in the expansion of healthcare infrastructure. Emerging economies are rapidly building hospitals, clinics, and distribution networks to make healthcare more accessible to their growing populations. This expansion is not limited to urban areas but extends to rural regions, which historically have been underserved. The increase in healthcare facilities necessitates a corresponding increase in pharmaceutical supplies, creating substantial opportunities for pharmaceutical companies to penetrate new markets and establish robust distribution channels.

Regulatory Heterogeneity

Regulatory heterogeneity serves as a key restraint in the pharmerging market. Emerging markets often have diverse and evolving regulatory frameworks that can vary significantly from one country to another. This variability can pose challenges for pharmaceutical companies looking to launch products simultaneously in multiple markets. Navigating these different regulatory environments requires significant resources and expertise, which can delay product launches and increase the cost of market entry.

Competition with Local Manufacturers

A major challenge in the pharmerging market is the competition posed by local pharmaceutical manufacturers. These local companies often have a better understanding of the regional market dynamics and regulatory nuances. They also benefit from established relationships within local healthcare systems and may be viewed more favorably by local consumers. Additionally, local manufacturers can often produce pharmaceuticals at a lower cost due to cheaper labor and materials, making it difficult for international companies to compete on price. This intense competition requires multinational pharmaceutical companies to innovate in terms of product offerings, market strategies, and pricing models to gain a foothold and expand their presence in these regions.

Market Segmentation by Product

In the pharmerging market, segmentation by product reveals that Pharmaceuticals and Healthcare are two significant categories. Pharmaceuticals consistently drive the highest revenue due to the persistent need for medications, driven by an increasing burden of diseases and expanding healthcare access in emerging markets. This segment benefits from both the widespread chronic conditions requiring ongoing pharmaceutical interventions and the acute treatments needed for communicable diseases. On the other hand, the Healthcare segment, encompassing services, healthcare IT, and medical equipment, is projected to experience the highest Compound Annual Growth Rate (CAGR). This surge is fueled by governmental efforts to improve healthcare infrastructure, increasing private investments in hospital facilities, and a growing emphasis on telemedicine and digital health solutions in response to the global push for more efficient healthcare delivery systems.

Market Segmentation by Indication

Market segmentation by indication includes Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and others. The segment for Cancer and Autoimmune Diseases is expected to witness the highest revenue, largely due to the high cost of treatments and ongoing pharmaceutical innovation aimed at these complex conditions. Additionally, the increasing prevalence of these diseases in emerging markets as populations age and adopt more Western lifestyles contributes to this trend. Conversely, the segment dealing with Lifestyle Diseases such as diabetes and hypertension is anticipated to register the highest CAGR. This growth is primarily driven by the rapid increase in these conditions among populations in emerging markets, spurred by changing diets, increasing urbanization, and more sedentary lifestyles.

Market Segmentation by Distribution Channel

Regarding the market segmentation by distribution channel, Hospitals and Retail Pharmacies are key players. Hospitals account for the highest revenue within this segment, as they are the primary health service delivery points offering both inpatient and outpatient care. The comprehensive care requirements and the need for specialized pharmaceuticals fuel their dominant revenue position. Retail Pharmacies are projected to see the highest CAGR, attributed to the growing trend of self-medication, increased accessibility, and the expansion of pharmacy networks across urban and rural areas. Moreover, the rising confidence in pharmaceutical retail through chain pharmacies and the growing acceptance of generic drugs play crucial roles in this growth. Additionally, e-commerce channels are rapidly gaining traction due to the convenience of online ordering and the increasing penetration of internet services, indicating a potential shift in consumer behavior in the pharmaceutical distribution landscape in emerging markets.

Regional Insights

In the pharmerging market, geographic trends highlight significant growth across various regions, with Asia-Pacific leading in terms of both the highest Compound Annual Growth Rate (CAGR) and revenue generation. In 2023, countries like China and India dominated the market revenue due to their large populations, increasing healthcare expenditure, and expanding pharmaceutical manufacturing capabilities. These nations have become hubs for pharmaceutical innovation and production, driven by supportive government policies and a rising middle class. Looking forward to the forecast period of 2024 to 2032, Asia-Pacific is expected to maintain its lead in growth rates due to ongoing urbanization, healthcare infrastructure improvements, and the increasing prevalence of chronic diseases. Latin America and Eastern Europe are also expected to witness notable growth, driven by similar trends of healthcare reforms and economic development, though their overall market share remains smaller compared to Asia-Pacific.

Competitive Trends

In terms of competitive trends, the pharmerging market is characterized by a mix of intense competition among leading pharmaceutical companies and dynamic entries by new regional players. In 2023, top players like Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd. showcased substantial revenues by leveraging their extensive product portfolios and robust distribution networks. These companies focused on strategic alliances, mergers, and acquisitions to consolidate their market positions, while also investing heavily in research and development to innovate new treatments for complex diseases. Looking into the forecast period of 2024 to 2032, these companies are expected to continue their emphasis on expanding into untapped markets, particularly focusing on generic drugs and biologics, which are anticipated to offer substantial growth opportunities. Additionally, local manufacturers in regions such as India and China are expected to strengthen their market presence by capitalizing on cost advantages and local regulatory support, thereby intensifying the competitive landscape. These trends are poised to define the strategic directions of the pharmerging market, with companies constantly adapting to the evolving healthcare demands and regulatory environments in these dynamic regions.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Pharmerging market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Pharmerging market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Product

• Pharmaceuticals

Branded Prescription Drugs

Generic Drugs

Branded Generics

Unbranded Generics

OTC Drugs

• Healthcare

Medical Devices

Diagnostic Instruments

Others (IT and Record Management)

Indication

• Lifestyle Diseases
• Cancer and Autoimmune Diseases
• Infectious Diseases
• Others

Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• E-commerce
• Drugs Stores

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Pharmerging market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmerging market?

Which is the largest regional market for Pharmerging market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmerging market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmerging market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Pharmerging Market
• 2.2. Global Pharmerging Market, By Product, 2023 (US$ Million)
• 2.3. Global Pharmerging Market, By Indication, 2023 (US$ Million)
• 2.4. Global Pharmerging Market, By Distribution Channel, 2023 (US$ Million)
• 2.5. Global Pharmerging Market, By Geography, 2023 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2023

3. Pharmerging Market: Competitive Analysis

• 3.1. Market Positioning of Key Pharmerging Market Vendors
• 3.2. Strategies Adopted by Pharmerging Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. Pharmerging Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Pharmerging Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Pharmerging Market: By Product, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Pharmaceuticals
    • 5.3.1.1. Branded Prescription Drugs
    • 5.3.1.2. Generic Drugs
      • 5.3.1.2.1. Branded Generics
      • 5.3.1.2.2. Unbranded Generics
    • 5.3.1.3. OTC Drugs
  • 5.3.2. Healthcare
    • 5.3.2.1. Medical Devices
    • 5.3.2.2. Diagnostic Instruments
    • 5.3.2.3. Others (IT and Record Management)

6. Pharmerging Market: By Indication, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Lifestyle Diseases
  • 6.3.2. Cancer and Autoimmune Diseases
  • 6.3.3. Infectious Diseases
  • 6.3.4. Others

7. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Retail Pharmacies
  • 7.3.4. E-commerce
  • 7.3.5. Drugs Stores

8. North America Pharmerging Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 8.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 8.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 8.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 8.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 8.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

9. UK and European Union Pharmerging Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 9.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 9.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 9.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 9.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 9.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

10. Asia Pacific Pharmerging Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 10.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 10.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 10.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 10.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 10.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

11. Latin America Pharmerging Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 11.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 11.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 11.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 11.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 11.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

12. Middle East and Africa Pharmerging Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
• 12.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
• 12.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
• 12.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
      • 12.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
      • 12.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

13. Company Profile

• 13.1. Abbott Laboratories
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. Koninklijke Philips N.V.
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. F. Hoffmann-La Roche Ltd.
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Merck & Co., Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Novartis AG
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Johnson & Johnson
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. Teva Pharmaceutical Industries Ltd.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. AstraZeneca
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. GlaxoSmithKline plc
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. Lupin
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Tata Consultancy Services Ltd.
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives
• 13.12. Sun Pharmaceutical Industries Ltd.
  • 13.12.1. Company Overview
  • 13.12.2. Financial Performance
  • 13.12.3. Product Portfolio
  • 13.12.4. Strategic Initiatives
• 13.13. Huadong Medicine Co., Ltd.
  • 13.13.1. Company Overview
  • 13.13.2. Financial Performance
  • 13.13.3. Product Portfolio
  • 13.13.4. Strategic Initiatives
• 13.14. Other Notable Players
  • 13.14.1. Company Overview
  • 13.14.2. Financial Performance
  • 13.14.3. Product Portfolio
  • 13.14.4. Strategic Initiatives